Jiaci

62 / 80

Practitioner's Corner
J Investig Allergol Clin Immunol 2019; Vol. 29(5): 378-398 © 2019 Esmon Publicidad
Manuscript received February 27, 2019; accepted for publication
May 3, 2019.
Manuel Jorge Rial
Victoria del Pozo
Instituto de Investigación Sanitaria
Hospital Universitario Fundacion Jimenez Diaz
Avenida Reyes Católicos, 2
28040 Madrid, Spain
E-mail:
miRNAs analyzed. The baseline expression values (2-ΔCt )
compared with the follow-up values were as follows: miR-
1246, 0.72 (0.33) vs 1.21 (0.89) (P=.34); miR-144-5p, 0.18
(0.11) vs 0.22 (0.22) (P =.70); miR-320a, 1.89 (0.75) vs
3.14 (2.30) (P=.22); miR-185-5p, 4.50 (1.95) vs 5.70 (2.53)
(P=.34); and miR-21-5p, 11.53 (2.59) vs 8.22 (5.32) (P =.19)
(Figure).
The lack of significant differences between baseline and
follow-up visits in asthmatic patients (whose therapy remained
unchanged) could mean that the miRNAs remain stable over
time in the same patient, with no change in therapy or clinical
parameters. Our hypothesis is that changes in the expression
of miRNAs in the same asthmatic patient over time could
be due to spontaneous modifications in health status or new
therapeutic interventions.
As expression of these miRNAs does not change
in clinically stable asthma patients, we can deduce that
their expression may prove useful for diagnosis when the
circumstances of asthma are unchanged.
To our knowledge, this is the first study to show the
stability of miRNAs over time in asthmatic patients in whom
no changes were made to treatment and no clinical changes
were observed. Stable miRNA expression implies that these
biomarkers may be used for diagnosis of asthma at different
time points during the disease course.
Funding
This study was supported by Fondo de Investigación
Sanitaria – FIS [PI15/00803, FI16/00036, PI18/00044],
FEDER (Fondo Europeo de Desarrollo Regional), Merck
Health Foundation funds and CIBER de Enfermedades
Respiratorias (CIBERES), a Carlos III Institute of Health
Initiative.
Conflicts of Interest
JS reports having served as a consultant to Thermo Fisher,
Novartis, Sanofi, Leti, FAES FARMA, Mundipharma, and
GSK and having received lecture fees from Novartis, GSK,
Stallergenes, LETI, and FAES FARMA. He has also received
grant support for research from Thermo Fisher and ALK.
VDP reports having served as a speaker/consultant to
AstraZeneca.
MJR, JMRM, and BS declare that they have no conflicts
of interest.
References
1. Loftus PA, Wise SK. Epidemiology of asthma. Curr Opin
Otolaryngol Head Neck Surg. 2016;24:245-9.
2. Maes T, Cobos FA, Schleich F, Sorbello V, Henket M, De Preter
K, et al. Asthma inflammatory phenotypes show differential
microRNA expression in sputum. J Allergy Clin Immunol.
2016;137:1433-46.
3. Sinha A, Yadav AK, Chakraborty S, Kabra SK, Lodha R, Kumar
M, et al. Exosome-enclosed microRNAs in exhaled breath hold
potential for biomarker discovery in patients with pulmonary
diseases. J Allergy Clin Immunol. 2013;132:219-22.
4. Yu H, Guan Z, Cuk K, Brenner H, ZhangY. Circulating microRNA
biomarkers for lung cancer detection in Western populations.
Cancer Med. 2018;7:4849-62.
5. Pattarayan D, Thimmulappa RK, Ravikumar V, Rajasekaran S.
Diagnostic Potential of Extracellular MicroRNA in Respiratory
Diseases. Clin Rev Allergy Immunol. 2018;54:480-92.
6. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK,
Pogosova-Agadjanyan EL, et al. Circulating microRNAs as
stable blood-based markers for cancer detection. Proc Natl
Acad Sci U S A. 2008;105:10513-8.
7. Grasedieck S, Schöler N, Bommer M, Niess JH,Tumani H, Rouhi
A, et al. Impact of serum storage conditions on microRNA
stability. Leukemia. 2012;26:2414-6.
8. Muñoz X, Álvarez-Puebla MJ, Arismendi E, Arochena L, Ausín
MDP, Barranco P, et al. The MEGA Project: A Study of the
Mechanisms Involved in the Genesis and Disease Course of
Asthma. Asthma Cohort Creation and Long-Term Follow-Up.
Arch Bronconeumol. 2018.54:378-85.
9. Plaza Moral V, Comité Ejecutivo de GEMA. [GEMA(4.0).
Guidelines for Asthma Management]. Arch Bronconeumol.
2015;51Suppl 51:2-54.
10. Rodrigo-Muñoz JM, Cañas JA, Sastre B, Rego N, Greif G,
Rial M, et al. Asthma diagnosis using integrated analysis of
eosinophil microRNAs. Allergy. 2019;74:507-17.
389